<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35503374</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1459</ISSN><JournalIssue CitedMedium="Internet"><Volume>269</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J Neurol</ISOAbbreviation></Journal><ArticleTitle>A SUMO4 initiator codon variant in amyotrophic lateral sclerosis reduces SUMO4 expression and alters stress granule dynamics.</ArticleTitle><Pagination><StartPage>4863</StartPage><EndPage>4871</EndPage><MedlinePgn>4863-4871</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-022-11126-7</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Recent evidence points toward a role of the small ubiquitin-like modifier (SUMO) system, including SUMO4, in protecting from stress insults and neurodegeneration, such as the progressive motor neuron disease amyotrophic lateral sclerosis (ALS), e.g., by regulating stress granule (SG) dynamics. Here, we investigated whether SUMO4 variants play a role in ALS pathogenesis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Whole-exome or targeted SUMO4 sequencing was done in 222 unrelated European ALS patients. The consequences of the identified initiator codon variant were analyzed at the mRNA, protein and cellular level. SUMO4 expression was quantified in human tissues. All patients were subjected to clinical, electrophysiological, and neuroradiological characterization.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A rare heterozygous SUMO4 variant, i.e., SUMO4:c.2T&gt;C p.Met1?, was detected in four of 222 (1.8%) ALS patients, significantly more frequently than in two control cohorts (0.3% each). SUMO4 mRNA and protein expression was diminished in whole blood or fibroblasts of a SUMO4 variant carrier versus controls. Pertinent stress factors, i.e., head trauma or cancer (treated by radiochemotherapy), were significantly more frequent in SUMO4 variant carrier versus non-carrier ALS patients. The mean number of SGs per cell was significantly higher in fibroblasts of a SUMO4 variant carrier compared to controls at baseline, upon oxidative stress, and after recovery, and SUMOylation of ALS-associated valosin-containing protein by SUMO4 was decreased. SUMO4 mRNA expression was highest in brain of all human tissues analyzed.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our results are consistent with SUMO4 haploinsufficiency as a contributor to ALS pathogenesis impacting SG dynamics and possibly acting in conjunction with environmental oxidative stress-related factors.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Osmanovic</LastName><ForeName>Alma</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-6012-8423</Identifier><AffiliationInfo><Affiliation>Department of Human Genetics, Hannover Medical School, Carl-Neuberg-Stra&#xdf;e 1, 30625, Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Hannover Medical School, Carl-Neuberg-Stra&#xdf;e 1, 30625, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>F&#xf6;rster</LastName><ForeName>Alisa</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7842-8483</Identifier><AffiliationInfo><Affiliation>Department of Human Genetics, Hannover Medical School, Carl-Neuberg-Stra&#xdf;e 1, 30625, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Widjaja</LastName><ForeName>Maylin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, Hannover Medical School, Carl-Neuberg-Stra&#xdf;e 1, 30625, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Auber</LastName><ForeName>Bernd</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, Hannover Medical School, Carl-Neuberg-Stra&#xdf;e 1, 30625, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Das</LastName><ForeName>Anibh M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Pediatric Kidney, Liver and Metabolic Diseases, Hannover Medical School, Carl-Neuberg-Stra&#xdf;e 1, 30625, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christians</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Human Genetics, Hannover Medical School, Carl-Neuberg-Stra&#xdf;e 1, 30625, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brand</LastName><ForeName>Frank</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-5537-8543</Identifier><AffiliationInfo><Affiliation>Department of Human Genetics, Hannover Medical School, Carl-Neuberg-Stra&#xdf;e 1, 30625, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Petri</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-9783-8584</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hannover Medical School, Carl-Neuberg-Stra&#xdf;e 1, 30625, Hannover, Germany. Petri.Susanne@mh-hannover.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Weber</LastName><ForeName>Ruthild G</ForeName><Initials>RG</Initials><Identifier Source="ORCID">0000-0001-6610-1080</Identifier><AffiliationInfo><Affiliation>Department of Human Genetics, Hannover Medical School, Carl-Neuberg-Stra&#xdf;e 1, 30625, Hannover, Germany. Weber.Ruthild@mh-hannover.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>PRACTIS-Clinician Scientist Program of Hannover Medical School</GrantID><Agency>Deutsche Forschungsgemeinschaft</Agency><Country/></Grant><Grant><GrantID>ME3696/3-1</GrantID><Agency>Deutsche Forschungsgemeinschaft</Agency><Country/></Grant><Grant><GrantID>KO5614/2-1</GrantID><Agency>Deutsche Forschungsgemeinschaft</Agency><Country/></Grant><Grant><GrantID>KlinStrucMed Program of Hannover Medical School</GrantID><Agency>Else Kr&#xf6;ner-Fresenius-Stiftung</Agency><Country/></Grant><Grant><GrantID>Hochschulinterne Leistungsf&#xf6;rderung</GrantID><Agency>Medizinischen Hochschule Hannover</Agency><Country/></Grant><Grant><GrantID>HiLF</GrantID><Agency>Medizinischen Hochschule Hannover</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018387">Codon, Initiator</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C489647">SUMO4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D025841">Small Ubiquitin-Related Modifier Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018387" MajorTopicYN="N">Codon, Initiator</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059472" MajorTopicYN="N">Exome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D025841" MajorTopicYN="N">Small Ubiquitin-Related Modifier Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000088162" MajorTopicYN="N">Stress Granules</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Cancer</Keyword><Keyword MajorTopicYN="N">Genetic risk</Keyword><Keyword MajorTopicYN="N">Head trauma</Keyword><Keyword MajorTopicYN="N">SUMOylation</Keyword><Keyword MajorTopicYN="N">Stress granules</Keyword></KeywordList><CoiStatement>AO received honoraria from Biogen; SP received honoraria from Biogen, Cytokinetics, Inc., Desitin Pharma, Novartis, Roche, and Teva. The other authors report no conflict of interest relevant to this study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>3</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35503374</ArticleId><ArticleId IdType="pmc">PMC9363285</ArticleId><ArticleId IdType="doi">10.1007/s00415-022-11126-7</ArticleId><ArticleId IdType="pii">10.1007/s00415-022-11126-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wolozin B, Ivanov P. Stress granules and neurodegeneration. Nat Rev Neurosci. 2019;20(11):649&#x2013;666. doi: 10.1038/s41583-019-0222-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41583-019-0222-5</ArticleId><ArticleId IdType="pmc">PMC6986315</ArticleId><ArticleId IdType="pubmed">31582840</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker LA, Huang B, Bieri G, Ma R, Knowles DA, Jafar-Nejad P, Messing J, Kim HJ, Soriano A, Auburger G, Pulst SM, Taylor JP, Rigo F, Gitler AD. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature. 2017;544(7650):367&#x2013;371. doi: 10.1038/nature22038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature22038</ArticleId><ArticleId IdType="pmc">PMC5642042</ArticleId><ArticleId IdType="pubmed">28405022</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Wang F, Hu Y, Chen R, Meng D, Guo L, Lv H, Guan J, Jia Y. In vivo stress granule misprocessing evidenced in a FUS knock-in ALS mouse model. Brain. 2020;143(5):1350&#x2013;1367. doi: 10.1093/brain/awaa076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa076</ArticleId><ArticleId IdType="pubmed">32358598</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosco DA, Lemay N, Ko HK, Zhou H, Burke C, Kwiatkowski TJ, Jr, Sapp P, McKenna-Yasek D, Brown RH, Jr, Hayward LJ. Mutant FUS proteins that cause amyotrophic lateral sclerosis incorporate into stress granules. Hum Mol Genet. 2010;19(21):4160&#x2013;4175. doi: 10.1093/hmg/ddq335.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq335</ArticleId><ArticleId IdType="pmc">PMC2981014</ArticleId><ArticleId IdType="pubmed">20699327</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang T, Xu W, Qin M, Yang Y, Bao P, Shen F, Zhang Z, Xu J. Pathogenic Mutations in the Valosin-containing Protein/p97(VCP) N-domain inhibit the SUMOylation of VCP and lead to impaired stress response. J Biol Chem. 2016;291(27):14373&#x2013;14384. doi: 10.1074/jbc.M116.729343.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M116.729343</ArticleId><ArticleId IdType="pmc">PMC4933190</ArticleId><ArticleId IdType="pubmed">27226613</ArticleId></ArticleIdList></Reference><Reference><Citation>Keiten-Schmitz J, Roder L, Hornstein E, Muller-McNicoll M, Muller S. SUMO: glue or solvent for phase-separated ribonucleoprotein complexes and molecular condensates? Front Mol Biosci. 2021;8:673038. doi: 10.3389/fmolb.2021.673038.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2021.673038</ArticleId><ArticleId IdType="pmc">PMC8138125</ArticleId><ArticleId IdType="pubmed">34026847</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchan JR, Kolaitis RM, Taylor JP, Parker R. Eukaryotic stress granules are cleared by autophagy and Cdc48/VCP function. Cell. 2013;153(7):1461&#x2013;1474. doi: 10.1016/j.cell.2013.05.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2013.05.037</ArticleId><ArticleId IdType="pmc">PMC3760148</ArticleId><ArticleId IdType="pubmed">23791177</ArticleId></ArticleIdList></Reference><Reference><Citation>Hendriks IA, Vertegaal AC. A comprehensive compilation of SUMO proteomics. Nat Rev Mol Cell Biol. 2016;17(9):581&#x2013;595. doi: 10.1038/nrm.2016.81.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm.2016.81</ArticleId><ArticleId IdType="pubmed">27435506</ArticleId></ArticleIdList></Reference><Reference><Citation>Marmor-Kollet H, Siany A, Kedersha N, Knafo N, Rivkin N, Danino YM, Moens TG, Olender T, Sheban D, Cohen N, Dadosh T, Addadi Y, Ravid R, Eitan C, Toth Cohen B, Hofmann S, Riggs CL, Advani VM, Higginbottom A, Cooper-Knock J, Hanna JH, Merbl Y, Van Den Bosch L, Anderson P, Ivanov P, Geiger T, Hornstein E. Spatiotemporal proteomic analysis of stress granule disassembly using APEX reveals regulation by SUMOylation and links to ALS pathogenesis. Mol Cell. 2020;80(5):876&#x2013;891.e6. doi: 10.1016/j.molcel.2020.10.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2020.10.032</ArticleId><ArticleId IdType="pmc">PMC7816607</ArticleId><ArticleId IdType="pubmed">33217318</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh SM, Liu Z, Okada M, Jang SW, Liu X, Chan CB, Luo H, Ye K. Ebp1 sumoylation, regulated by TLS/FUS E3 ligase, is required for its anti-proliferative activity. Oncogene. 2010;29(7):1017&#x2013;1030. doi: 10.1038/onc.2009.411.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/onc.2009.411</ArticleId><ArticleId IdType="pmc">PMC2824779</ArticleId><ArticleId IdType="pubmed">19946338</ArticleId></ArticleIdList></Reference><Reference><Citation>Osmanovic A, Widjaja M, F&#xf6;rster A, Weder J, Wattjes MP, Lange I, Sarikidi A, Auber B, Raab P, Christians A, Preller M, Petri S, Weber RG. SPG7 mutations in amyotrophic lateral sclerosis: a genetic link to hereditary spastic paraplegia. J Neurol. 2020;267(9):2732&#x2013;2743. doi: 10.1007/s00415-020-09861-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-09861-w</ArticleId><ArticleId IdType="pmc">PMC7419373</ArticleId><ArticleId IdType="pubmed">32447552</ArticleId></ArticleIdList></Reference><Reference><Citation>Labra J, Menon P, Byth K, Morrison S, Vucic S. Rate of disease progression: a prognostic biomarker in ALS. J Neurol Neurosurg Psychiatry. 2016;87(6):628&#x2013;632. doi: 10.1136/jnnp-2015-310998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-310998</ArticleId><ArticleId IdType="pubmed">26152368</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskarsson B, Horton DK, Mitsumoto H. Potential environmental factors in amyotrophic lateral sclerosis. Neurol Clin. 2015;33(4):877&#x2013;888. doi: 10.1016/j.ncl.2015.07.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ncl.2015.07.009</ArticleId><ArticleId IdType="pmc">PMC4646848</ArticleId><ArticleId IdType="pubmed">26515627</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez JY, White DJ, Hartenstein V, Eliceiri K, Tomancak P, Cardona A. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9(7):676&#x2013;682. doi: 10.1038/nmeth.2019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.2019</ArticleId><ArticleId IdType="pmc">PMC3855844</ArticleId><ArticleId IdType="pubmed">22743772</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohren KM, Nadkarni V, Song JH, Gabbay KH, Owerbach D. A M55V polymorphism in a novel SUMO gene (SUMO-4) differentially activates heat shock transcription factors and is associated with susceptibility to type I diabetes mellitus. J Biol Chem. 2004;279(26):27233&#x2013;27238. doi: 10.1074/jbc.M402273200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M402273200</ArticleId><ArticleId IdType="pubmed">15123604</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo D, Li M, Zhang Y, Yang P, Eckenrode S, Hopkins D, Zheng W, Purohit S, Podolsky RH, Muir A, Wang J, Dong Z, Brusko T, Atkinson M, Pozzilli P, Zeidler A, Raffel LJ, Jacob CO, Park Y, Serrano-Rios M, Larrad MT, Zhang Z, Garchon HJ, Bach JF, Rotter JI, She JX, Wang CY. A functional variant of SUMO4, a new I kappa B alpha modifier, is associated with type 1 diabetes. Nat Genet. 2004;36(8):837&#x2013;841. doi: 10.1038/ng1391.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1391</ArticleId><ArticleId IdType="pubmed">15247916</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Xie W, Liu Z, Shan H, Chen M, Song Y, Yu H, Lai L, Li Z. CRISPR start-loss: a novel and practical alternative for gene silencing through base-editing-induced start codon mutations. Mol Ther Nucleic Acids. 2020;21:1062&#x2013;1073. doi: 10.1016/j.omtn.2020.07.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2020.07.037</ArticleId><ArticleId IdType="pmc">PMC7452150</ArticleId><ArticleId IdType="pubmed">32854061</ArticleId></ArticleIdList></Reference><Reference><Citation>Baczyk D, Audette MC, Drewlo S, Levytska K, Kingdom JC. SUMO-4: A novel functional candidate in the human placental protein SUMOylation machinery. PLoS One. 2017;12(5):e0178056. doi: 10.1371/journal.pone.0178056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0178056</ArticleId><ArticleId IdType="pmc">PMC5435238</ArticleId><ArticleId IdType="pubmed">28545138</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>